Search

Introduction: Hyponatremia is the most common electrolyte disorder often present in peritoneal dialysis (PD) patients. The aim of this retrospective study was to investigate the effect of hyponatremia on mortality in patients undergoing PD. Methods: The health records of adult individuals with an inserted PD catheter identified via the centralized national e‐health database were used. Results: The mean age of the 846 patients included in the study was 52.48 years (±14.6). The mean sodium level was 136.51 mEq/L. Sodium levels <137 mEq/L were associated with higher death risk independent of comorbidities. There was a 0.821 times less reduction in mortality for each mEq /L increase in serum sodium. Conclusion: Our study provides evidence that monitoring and adjusting serum sodium levels is crucial in managing PD patients with hyponatremia, as low serum sodium level was found to be a significant and independent predictor of mortality. [ABSTRACT FROM AUTHOR]

Background: It is well documented that patients with chronic metabolic diseases, such as diabetes and obesity, are adversely affected by the COVID‐19 pandemic. However, when the subject is rare metabolic diseases, there are not enough data in the literature. Aim: To investigate the course of COVID‐19 among patients with Gaucher disease (GD), the most common lysosomal storage disease. Methods: Based on the National Health System data, a retrospective cohort of patients with confirmed (polymerase chain reactionpositive) COVID‐19 infection (n = 149 618) was investigated. The adverse outcomes between patients with GD (n = 39) and those without GD (n = 149 579) were compared with crude and propensity score‐matched (PSM) groups. The outcomes were hospitalisation, the composite of intensive care unit (ICU) admission and/or mechanical ventilation and mortality. Results: The patients with GD were significantly older and had a higher frequency of hypertension (HT), Type 2 diabetes mellitus (T2DM), dyslipidaemia, asthma or chronic obstructive pulmonary disease, chronic kidney disease, coronary artery disease, heart failure and cancer. Although hospitalisation rates in Gaucher patients were found to be higher in crude analyses, the PSM models (model 1, age and gender matched; model 2, matched for age, gender, HT, T2DM and cancer) revealed no difference for the outcomes between patients with GD and the general population. According to multivariate regression analyses, having a diagnosis of GD was not a significant predictor for hospitalisation (P = 0.241), ICU admission/mechanical ventilation (P = 0.403) or mortality (P = 0.231). Conclusion: According to our national data, SARS‐CoV‐2 infection in patients with GD does not have a more severe course than the normal population. [ABSTRACT FROM AUTHOR]

Background: There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID‐19) disease outcomes and mortality. Here, we evaluated COVID‐19 infection outcomes and mortality in thyroid cancer patients with COVID‐19 infection. Design and methods: We included a cohort of patients with thyroid cancer with PCR‐confirmed COVID‐19 disease from 11 March to 30 May 2020 from the Turkish Ministry of Health database in our nationwide, retrospective study. We compared the mortality and morbidity of COVID patients with or without thyroid cancer. Univariate and multivariate analyses were used to assess the independent factors for mortality, length of hospital stay and intensive care unit (ICU) admission and mechanical ventilation. We also analysed the effect of radioiodine treatment on severity and death rate of COVID‐19 disease. Results: We evaluated 388 COVID‐19 patients with thyroid cancer [median age: 54 years, interquartile range (IQR) 18 years, males: 23%] and age and gender‐matched 388 COVID‐19 patients without thyroid cancer. Patients with thyroid cancer had a similar mortality ratio compared with the non‐cancer group. Among patients with thyroid cancer, age, presence of diabetes mellitus, asthma/COPD, heart failure, chronic kidney disease, prior coronary artery disease, RAS blocker usage and low lymphocyte count were associated with mortality. Radioactive iodine (RAI) treatment and cumulative radioactive iodine dosage did not negatively affect the severity and mortality of COVID‐19 disease in our patient group. Conclusions: Our study indicated that history of thyroid cancer did not have an increased risk of mortality or morbidity in COVID‐19 disease. Besides, RAI therapy history and doses of radioactive iodine did not affect mortality or outcome. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Diabetes is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

In this study, we aim to report the outcomes for COVID‐19 in patients with hematological malignancy in Turkey. Data from laboratory‐confirmed 188 897 COVID‐19 patients diagnosed between 11 March 2020 and 22 June 2020 included in the Republic of Turkey, Ministry of Health database were analyzed retrospectively. All COVID‐19 patients with hematological malignancy (n = 740) were included in the study and an age, sex, and comorbidity‐matched cohort of COVID‐19 patients without cancer (n = 740) at a 1:1 ratio was used for comparison. Non‐Hodgkin lymphoma (30.1%), myelodysplastic syndrome (19.7%), myeloproliferative neoplasm (15.7%) were the most common hematological malignancies. The rates of severe and critical disease were significantly higher in patients with hematological malignancy compared with patients without cancer (P =.001). The rates of hospital and intensive care unit (ICU) admission were higher in patients with hematological malignancy compared with the patients without cancer (P =.023, P =.001, respectively). The length of hospital stay and ICU stay was similar between groups (P =.7, P =.3, retrospectively). The rate of mechanical ventilation (MV) support was higher in patients with hematological malignancy compared with the control group (P =.001). The case fatality rate was 13.8% in patients with hematological malignancy, and it was 6.8% in the control group (P =.001). This study reveals that there is an increased risk of COVID‐19‐related serious events (ICU admission, MV support, or death) in patients with hematological malignancy compared with COVID‐19 patients without cancer and confirms the high vulnerability of patients with hematological malignancy in the current pandemic. Highlights: This study shows that there is an increased risk of COVID‐19‐related serious events (ICU admission, MV support, or death) in patients with hematological malignancy compared with COVID‐19 patients without cancer.The study reveals high vulnerability of patients with hematological malignancy in the current pandemic. [ABSTRACT FROM AUTHOR]